Reneo Pharmaceuticals, Inc. announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Mr. Hoelscher, Kenneth Harrison, Partner at Novo Ventures (US) Inc., resigned from the Reneo Board of Directors.

Reneo also announced that Lon Cardon, Ph.D. will not seek re-election to its Board of Directors at the upcoming 2022 annual meeting of shareholders. Dr. Cardon recently assumed the role of President and Chief Executive Officer of The Jackson Laboratory, a non-profit biomedical research institution, and due to institutional policy will be unable to serve on the Board beyond his current term. Mr. Hoelscher currently serves as Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, a biotech company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.